Volastra Therapeutics founded by Charles Hugh-Jones, is at the forefront of a new wave of biotechnology startups, focused on harnessing the power of chromosomal instability (CIN) to create innovative cancer therapies. With a recent Series A funding round of $60 million and a team of world-class investors including Eli Lilly and Company, ARCH Venture Partners, Polaris Partners, Catalio Capital Management, Droia Ventures, and Vida Ventures LLC, Volastra is poised to change the game in the fight against cancer. Their proprietary CINtech platform, which leverages a deep understanding of CIN and its biological consequences, enables them to identify relevant targets more quickly, create first-in-class drugs, and select the best patients for their therapies. 

With a multi-pronged therapeutic strategy that includes synthetic lethality and immune activation, Volastra is working to stop cancer in its tracks. Their approach represents a major shift in biotech research, with a focus on targeting CIN itself rather than the genetic mutations that result from it. Volastra is poised to revolutionize how cancer is treated, and their groundbreaking work is sure to be a game-changer in the biotechnology industry.